ID   MGH121
AC   CVCL_DH49
DR   GEO; GSM1568547
DR   Wikidata; Q54905473
RX   PubMed=25758528;
RX   PubMed=25964297;
RX   PubMed=26828195;
CC   Characteristics: Erlotinib resistant (PubMed=25758528).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (PubMed=25758528).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C2926; Lung non-small cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 8
//
RX   PubMed=25758528; DOI=10.1038/ncomms7377; PMCID=PMC4357281;
RA   Niederst M.J., Sequist L.V., Poirier J.T., Mermel C.H.,
RA   Lockerman E.L., Garcia A.R., Katayama R., Costa C., Ross K.N.,
RA   Moran T., Howe E., Fulton L.E., Mulvey H.E., Bernardo L.A.,
RA   Mohamoud F., Miyoshi N., VanderLaan P.A., Costa D.B., Janne P.A.,
RA   Borger D.R., Ramaswamy S., Shioda T., Iafrate A.J., Getz G.,
RA   Rudin C.M., Mino-Kenudson M., Engelman J.A.;
RT   "RB loss in resistant EGFR mutant lung adenocarcinomas that transform
RT   to small-cell lung cancer.";
RL   Nat. Commun. 6:6377.1-6377.10(2015).
//
RX   PubMed=25964297; DOI=10.1158/1078-0432.CCR-15-0560; PMCID=PMC4587765;
RA   Niederst M.J., Hu H.-C., Mulvey H.E., Lockerman E.L., Garcia A.R.,
RA   Piotrowska Z., Sequist L.V., Engelman J.A.;
RT   "The allelic context of the C797S mutation acquired upon treatment
RT   with third-generation EGFR inhibitors impacts sensitivity to
RT   subsequent treatment strategies.";
RL   Clin. Cancer Res. 21:3924-3933(2015).
//
RX   PubMed=26828195; DOI=10.1038/nm.4040; PMCID=PMC4900892;
RA   Hata A.N., Niederst M.J., Archibald H.L., Gomez-Caraballo M.,
RA   Siddiqui F.M., Mulvey H.E., Maruvka Y.E., Ji F., Bhang H.-e.C.,
RA   Krishnamurthy Radhakrishna V., Siravegna G., Hu H.-C., Raoof S.,
RA   Lockerman E.L., Kalsy A., Lee D., Keating C.L., Ruddy D.A., Damon L.J.,
RA   Crystal A.S., Costa C., Piotrowska Z., Bardelli A., Iafrate A.J.,
RA   Sadreyev R.I., Stegmeier F., Getz G., Sequist L.V., Faber A.C.,
RA   Engelman J.A.;
RT   "Tumor cells can follow distinct evolutionary paths to become
RT   resistant to epidermal growth factor receptor inhibition.";
RL   Nat. Med. 22:262-269(2016).
//